123 related articles for article (PubMed ID: 37808840)
1. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N; Kabotyanski EB; Saltzman AB; Malovannaya A; Yuan X; Reineke LC; Lieu N; Gao Y; Pedroza DA; Calderon SJ; Smith AJ; Hamor C; Safari K; Savage S; Zhang B; Zhou J; Solis LM; Hilsenbeck SG; Fan C; Perou CM; Rosen JM
bioRxiv; 2023 Sep; ():. PubMed ID: 37808840
[TBL] [Abstract][Full Text] [Related]
2. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.
Zhao N; Kabotyanski EB; Saltzman AB; Malovannaya A; Yuan X; Reineke LC; Lieu N; Gao Y; Pedroza DA; Calderon SJ; Smith AJ; Hamor C; Safari K; Savage S; Zhang B; Zhou J; Solis LM; Hilsenbeck SG; Fan C; Perou CM; Rosen JM
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37874652
[TBL] [Abstract][Full Text] [Related]
3. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
Gerson-Gurwitz A; Young NP; Goel VK; Eam B; Stumpf CR; Chen J; Fish S; Barrera M; Sung E; Staunton J; Chiang GG; Webster KR; Thompson PA
Front Oncol; 2021; 11():766298. PubMed ID: 34900714
[TBL] [Abstract][Full Text] [Related]
4. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.
Boyer JA; Sharma M; Dorso MA; Mai N; Amor C; Reiter JM; Kannan R; Gadal S; Xu J; Miele M; Li Z; Chen X; Chang Q; Pareja F; Worland S; Warner D; Sperry S; Chiang GG; Thompson PA; Yang G; Ouerfelli O; de Stanchina E; Wendel HG; Rosen EY; Chandarlapaty S; Rosen N
bioRxiv; 2024 May; ():. PubMed ID: 38766126
[TBL] [Abstract][Full Text] [Related]
5. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
8. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
[No Abstract] [Full Text] [Related]
9. Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
Ho JJD; Cunningham TA; Manara P; Coughlin CA; Arumov A; Roberts ER; Osteen A; Kumar P; Bilbao D; Krieger JR; Lee S; Schatz JH
Cell Rep; 2021 Oct; 37(2):109806. PubMed ID: 34644561
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.
Sridharan S; Robeson M; Bastihalli-Tukaramrao D; Howard CM; Subramaniyan B; Tilley AMC; Tiwari AK; Raman D
Front Oncol; 2019; 9():1311. PubMed ID: 31867270
[TBL] [Abstract][Full Text] [Related]
11. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
13. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
14. The Streptococcus virulence protein PepO triggers anti-tumor immune responses by reprograming tumor-associated macrophages in a mouse triple negative breast cancer model.
Liu B; Huang J; Xiao J; Xu W; Zhang H; Yuan Y; Yin Y; Zhang X
Cell Biosci; 2023 Nov; 13(1):198. PubMed ID: 37925462
[TBL] [Abstract][Full Text] [Related]
15. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
16. Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
Bagati A; Kumar S; Jiang P; Pyrdol J; Zou AE; Godicelj A; Mathewson ND; Cartwright ANR; Cejas P; Brown M; Giobbie-Hurder A; Dillon D; Agudo J; Mittendorf EA; Liu XS; Wucherpfennig KW
Cancer Cell; 2021 Jan; 39(1):54-67.e9. PubMed ID: 33385331
[TBL] [Abstract][Full Text] [Related]
17. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G; Romero Y; Thevarajan I; Zolkiewska A
Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
[TBL] [Abstract][Full Text] [Related]
18. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
Front Oncol; 2021; 11():648139. PubMed ID: 34094935
[TBL] [Abstract][Full Text] [Related]
20. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
